Ken began his doctoral studies in 1998 in the laboratory of Tyler Jacks at the MIT Centre for Cancer Research, investigating the neomorphic effects of mutant p53 in a mouse model of Li-Fraumeni Syndrome. While at MIT, he also helped develop a conditional mutant model of advanced lung adenocarcinoma. After graduating in 2005, Ken began a postdoctoral fellowship in the laboratory of David Tuveson at the University of Pennsylvania, later moving with the lab to the University of Cambridge in England. There he built a translational research facility for studying novel anticancer therapeutics in genetically engineered mouse models of pancreatic cancer. Ken joined the faculty of the Columbia University Herbert Irving Comprehensive Cancer Centre in January of 2010, where he is continuing his investigations into the response of pancreatic tumours to therapeutic interventions. He also founded and directs the Oncology Precision Therapeutics Imaging Core within the Herbert Irving Comprehensive Cancer Centre. Most recently, he was appointed as the Director of GI Translational Research within the Department of Medicine at Columbia University Medical Centre. In this capacity he is responsible for building interdisciplinary teams within the GI space, focusing specifically between the research laboratory and clinic. He has also recently been appointed as the Co-leader of the Herbert Irving Comprehensive Cancer Centre’s Cancer Systems Biology program.
Last update: May 2022